

MAIL DATE **CANCELLED**

OCT 1 5 2001

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	09/922,378
Filing Date	August 3, 2001
First Named Inventor	William A. Horne
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket No.	480140.428D3

TECH CENTER 1600/2900

OCT 1 7 2001



RECEIVED

ENCLOSURES (check all that apply)

- | | | |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> CD(s), Number
of CD(s) _____ |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance
Communication to Group |
| <input type="checkbox"/> Amendment/Response | <input type="checkbox"/> Request for Corrected Filing
Receipt | <input type="checkbox"/> Appeal Communication to
Board of Appeals and
Interferences |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to
Group (Appeal Notice, Brief,
Reply Brief) |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Petition to Convert to a
Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Express Abandonment
Request | <input type="checkbox"/> Power of Attorney,
Revocation, Change of
Correspondence Address | <input checked="" type="checkbox"/> Return Postcard |
| <input checked="" type="checkbox"/> Information Disclosure
Statement; Form PTO-1449 | <input type="checkbox"/> Declaration | <input type="checkbox"/> Additional Enclosure(s)
(please identify below): |
| <input type="checkbox"/> Cited References | <input type="checkbox"/> Statement under 37 CFR
3.73(b) | _____ |
| <input type="checkbox"/> Certified Copy of Priority
Document(s) | <input type="checkbox"/> Terminal Disclaimer | _____ |
| <input type="checkbox"/> Response to Missing Parts
under 37 C.F.R. 1.52 or 1.53 | <input type="checkbox"/> Small Entity Statement | _____ |
| <input type="checkbox"/> Response to Missing
Parts/Incomplete Application | <input type="checkbox"/> Request for Refund | _____ |


Remarks


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	William T. Christiansen, Ph.D.	 00500 PATENT TRADEMARK OFFICE
Signature		
Date	10/10/01	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.

Typed or printed name	Nathan Adderson	
Signature		Date: 10/11/01



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : William A. Horne and Tilman Oltersdorf
Application No. : 09/922,378
Filed : August 3, 2001
For : HUMAN BAD POLYPEPTIDES, ENCODING
NUCLEIC ACIDS AND METHODS OF USE

RECEIVED

OCT 17 2001

TECH CENTER 1600/2900

Docket No. : 480140.428D3
Date : October 10, 2001

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the 14 references set forth on the attached Form PTO-1449. This application is a divisional and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/376,154 filed August 17, 1999; which is a divisional of Application No. 08/717,123, filed September 20, 1996. The references listed on the attached Form PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request.

As to any reference made of record on the attached Form PTO-1449, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is

believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



William T. Christiansen, Ph.D.

Registration No. 44,614

WTC:nka

Enclosures:

Postcard

Form PTO/SB/21

Form PTO-1449

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

D:\NrPortbl\iManage\NATHANA\222556_1.DOC

FORM 1449
 (REV. 7-80)

MAILED & CANCELLED
 OCT 15 2001

U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
 480140.428D3

APPLICATION NO.
 09/922,378

APPLICANTS
 William A. Horne and Tilman Oltersdorf

FILING DATE
 August 3, 2001

GROUP ART UNIT
 Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT
 (Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,683,195	7/28/87	Mullis et al.	435	6	
	AB	4,683,202	7/28/87	Mullis	435	91.2	
	AC	4,754,065	6/28/88	Levenson et al.	562	564	
	AD	4,800,159	1/24/89	Mullis et al.	435	91.2	
	AE	5,352,771	10/4/94	Kostic et al.	530	345	
	AF	5,663,316	9/2/97	Xudong	536	23.5	
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AH	WO 96/13614	5/9/96	WIPO		
	AI					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AJ	Gyuris et al., "Cdk2, a Human G1 and S Phase Protein Phosphates That Associates with Cdk2," <i>Cell</i> 75: 791-803, 1993.
	AK	Ruden et al., "Generating Yeast Transcriptional Activators Containing No Yeast Protein Sequences," <i>Nature</i> 350: 250-252, 1991.
	AL	Sato et al., "Interactions Among Members of the Bcl-2 Protein Family Analyzed with a Yeast Two-Hybrid System," <i>Proc. Natl. Acad. Sci. USA</i> 91: 9238-9242, 1994.
	AM	Sinkovics et al., "Apoptosis by Genetic Engineering," <i>Leukemia</i> 8(1): S98-S102, 1994.
	AN	Ross et al., "Gene Therapy in the United States: A Five-Year Status Report," <i>Human Gene Therapy</i> 7: 1781-1790, 1996.
	AO	Wolff et al., "Direct Gene Transfer into Mouse Muscle in Vivo," <i>Science</i> 247: 1465-1468, 1990.
	AP	Yang et al., "Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death," <i>Cell</i> 80: 285-291, January 27, 1995.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED

OCT 17 2001
TECH CENTER 1600/2900